- End-tidal Control software helps reduce greenhouse gas emissions and costs by cutting anesthetic agent waste
- Enables anesthesia providers to set precise targets for oxygen and anesthetic agent
- Offers increased workflow efficiencies by reducing the manual inputs providers must enter in delivering agent and oxygen
CHICAGO – April 4, 2022 – GE Healthcare announced today the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2
For media inquiries, please contact:
Global Communications Director, Life Care Solutions
GE Healthcare
+1 414 305 1710
[email protected]
business unit
tags